ARTICLE | Finance
Lumira to invest $35M ‘bespoke’ fund with Italy’s Angelini as sole backer
Angelini Lumira Biosciences Fund will invest in CNS and rare disease therapies
July 28, 2021 10:42 PM UTC
Two days after Lumira announced the closing of its $220 million fourth fund, the firm has identified Angelini as the sole investor in the $35 million Angelini Lumira Biosciences Fund, a separate vehicle designed to invest in therapies for CNS disorders and rare diseases.
Lumira Ventures’ Gerry Brunk told BioCentury earlier this week that the two funds may co-invest in companies at times, but said the Angelini Pharma S.p.A.-backed fund isn’t designed to be a co-investment fund with Lumira Ventures IV...